A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINS
Clinical Trial Grant
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
June 15, 2020
End Date
June 30, 2023
Administered By
Duke Human Vaccine Institute
Awarded By
Pfizer, Inc.
Start Date
June 15, 2020
End Date
June 30, 2023